Abstract
There is an urgent need for the identification and validation of new therapeutic targets in protozoan parasites because currently available drugs are limited in number and usefulness, and no vaccines are available. The discovery that alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, is an efficacious treatment for African Sleeping Sickness caused by the protozoan parasite Trypanosoma brucei, has validated the polyamine pathway as a target in protozoan parasites. Polyamines are ubiquitous organic cations that play critical roles in key cellular processes such as growth, differentiation, and macromolecular biosynthesis. In recent years, remarkable progress has been made in the characterization of the polyamine pathway in a variety of protozoan parasites and this review will highlight surprising and unique features that could lead to new therapeutic strategies.
Keywords: Polyamines, parasites, Trypanosoma brucei, Trypanosoma cruzi, Leishmania, Plasmodium, therapeutic strategies.
Current Pharmaceutical Design
Title:Parasite Polyamines as Pharmaceutical Targets
Volume: 23 Issue: 23
Author(s): Sigrid Roberts*Buddy Ullman
Affiliation:
- Pacific University School of Pharmacy, Hillsboro, OR 9712,United States
Keywords: Polyamines, parasites, Trypanosoma brucei, Trypanosoma cruzi, Leishmania, Plasmodium, therapeutic strategies.
Abstract: There is an urgent need for the identification and validation of new therapeutic targets in protozoan parasites because currently available drugs are limited in number and usefulness, and no vaccines are available. The discovery that alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, is an efficacious treatment for African Sleeping Sickness caused by the protozoan parasite Trypanosoma brucei, has validated the polyamine pathway as a target in protozoan parasites. Polyamines are ubiquitous organic cations that play critical roles in key cellular processes such as growth, differentiation, and macromolecular biosynthesis. In recent years, remarkable progress has been made in the characterization of the polyamine pathway in a variety of protozoan parasites and this review will highlight surprising and unique features that could lead to new therapeutic strategies.
Export Options
About this article
Cite this article as:
Roberts Sigrid*, Ullman Buddy , Parasite Polyamines as Pharmaceutical Targets, Current Pharmaceutical Design 2017; 23(23) . https://dx.doi.org/10.2174/1381612823666170601101644
DOI https://dx.doi.org/10.2174/1381612823666170601101644 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews Tuberculous Pericarditis
Current Cardiology Reviews Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Lung Ultrasound in the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Beta-Blockers are Associated with Decreased In-Hospital Mortality and Stroke in Acute Decompensated Heart Failure: Findings from a Retrospective Analysis of a 22-Year Registry in the Middle East (1991-2013)
Current Vascular Pharmacology Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Moxifloxacin-induced Hypoglycemia in a Non-diabetic Patient
Current Drug Safety